Dissecting the chemical signals that determine dietary xenobiotic metabolism in the GUT microbiome
Active Project Grant Awarded Last action
- Award ID
- F31AI194800
- Recipient
-
Yale Univ UEI FL6GV84CKN57
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $100,228
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 0% complete
- Originally
- Place of performance
- Connecticut, USA
Award details come from USAspending.gov.
About this award
The National Institute of Allergy and Infectious Diseases awarded Yale University $100,228 on November 26, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research dissecting the chemical signals that determine dietary xenobiotic metabolism in the gut microbiome.
The funded research examines how gut bacterial communities metabolize dietary compounds, specifically rebaudioside A (the main compound in stevia), through substrate-independent signaling pathways rather than direct response to the target substrate itself. The investigator has identified a small molecule that activates rebaudioside A metabolism by Bacteroides xylanisolvens, determined a gene locus necessary for this metabolism, and demonstrated that this substrate-independent regulation extends to other dietary compounds beyond stevia. The work addresses interpersonal variability in human stevia response and how circulating bacterial metabolite profiles differ based on microbiome composition, with potential implications for host glucose sensitivity and hyperglycemia.
Work is performed in Connecticut. The period of performance runs through May 31, 2028.
Description
- Abstract
- The GUT microbiome encodes an immense repertoire of metabolic enzymes that shape the diet-microbiome- host interface by performing diverse chemical transformations on dietary small molecules. The GUT microbiome can only metabolize a specific dietary compound if IT both encodes and expresses the necessary metabolic enzymes. Typically, bacterial cells upregulate metabolic enzyme expression in response to the target substrate or its breakdown products. However, we have discovered that human GUT bacteroidetes integrate orthologous environmental signals into their metabolic gene regulation. GUT microbial metabolism of the widely-used artificial sweetener stevia follows this pattern: specific GUT bacterial species and human microbiome communities metabolize the main compound in stevia, rebaudioside a (REBA), but this metabolism is regulated by orthogonal signals and not REBA itself. This microbial metabolism and its novel regulation strategy may impact why humans exhibit interpersonal variability in their stevia response: stevia is linked to contradictory outcomes in host glucose sensitivity and hyperglycemia, and bacterial REBA metabolites circulate in humans following stevia consumption. This proposal presents a plan to define the substrate-independent signaling pathways that activate REBA metabolism in GUT microbes and determine how these pathways modulate host response to these compounds. I have identified a small molecule that activates REBA metabolism by the common GUT commensal bacteroides xylanisolvens, determined a gene locus necessary for REBA metabolism in this bacterium, discovered this substrate-independent metabolism applies to other dietary compounds beyond REBA, shown that human microbiomes exhibit extensive interpersonal variation in REBA metabolism, and demonstrated that circulating metabolite profiles in the host differ based on the REBA metabolic capacity of their microbiome. In aim 1, I will characterize the substrate-independent mechanism that activates metabolism of diverse dietary glycosides, including REBA, by B. Xylanisolvens and assess whether the abundance of these metabolic genes can explain metabolic variability across human microbiomes. In aim 2, I will investigate REBA metabolism and its consequences for host physiology and hyperglycemia in vivo. If successful, my research will uncover a unique regulatory paradigm for bacterial dietary compound metabolism and whether GUT microbial catabolism of a widely-consumed artificial sweetener can modulate host metabolic health. This project will provide learning opportunities scientifically to execute cutting-edge microbiology, biochemistry, pharmacology, analytical chemistry, endocrinology, and genetics research and professionally to improve teaching, mentorship, and scientific writing and presentation skills. I am confident this project, these training plans at yale university, and support from my thesis advisor DR. Andrew goodman will advance my development as an independent scientist in preparation for a research career.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $50,114 | |
| Amendment | $0 | |
| Original award | $50,114 |
Quick answers
Who received award F31AI194800?
F31AI194800 was awarded to Yale Univ by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on November 26, 2026.
How much is award F31AI194800 worth?
$100,228 has been obligated on F31AI194800.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award